AN2 Therapeutics has signed an exclusive licence agreement with the University of Georgia Research Foundation to advance the development of a new boron-containing small molecule to treat Chagas disease.
The boron-based molecules were initially discovered by a team of researchers from Pfizer‘s wholly-owned subsidiary Anacor Pharmaceuticals and the University of Georgia, using non-dilutive grant funding from Wellcome.
Go deeper with GlobalData
The key compound in this series, AN2-502998, was discovered in partnership with Professor Rick Tarleton from the University of Georgia.
Wellcome has supported preclinical activities, carried out in collaboration with Tarleton.
AN2 Therapeutics co-founder, president and CEO Eric Easom stated: “AN2-502998 is the only compound to date that demonstrates complete cures of infection in non-human primates with long-term, naturally acquired chronic infections of diverse T cruzi genetic types.
See Also:
“Professor Tarleton and scientists from AN2 have advanced this research, and with IND-enabling preclinical studies for AN2-502998 well underway and this licence in hand, we are excited to further develop AN2-502998 as a potential treatment for Chagas disease.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe World Health Organisation (WHO) declared Chagas disease to be a neglected tropical disease.
It is caused by the Trypanosoma cruzi (T cruzi) parasite that spreads through a subspecies of blood-feeding insects commonly known as “kissing bugs”.
The WHO estimates that seven million people worldwide are infected with the parasite.
